Enzalutamide plus androgen-deprivation therapy (ADT) improved 5-yr overall survival significantly in patients with metastatic hormone-sensitive prostate cancer, with a 30% reduced risk of death versus placebo plus ADT. Survival benefits of enzalutamide were consistent across subgroups, including a notable 36-mo gain in patients with high-volume disease.
European Urology published a clinical update in Research Highlights on 02 Feb 2026.
The item focuses on ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
Review the original article for the full source wording and details.